The modality of huoxue-huayu in treatment of retinal vein occlusion.
BACKGROUND
There were some reports in China about Huoxue-Huayu therapy on retinal vein occlusion (RVO), but prospective and systematic studies are very few. The curative effect and mechanism of this therapy on RVO have not been reported previously.


METHODS
80 patients with RVO were randomly divided into 2 groups, Fundus III (group A) and urokinase group (group B). Group A was treated by Fundus III oral liquid (a composite herbal recipe for Huoxue-Huayu or invigoration of blood circulation and reduction of blood stasis) 10ml/time P.O. t.i.d. The treatment course was 1 mouth. Group B was treated by urokinase. The urokinase that produced in China was used 10,000 u + 5% glucose 500ml/day i.v. drip for 5 days in a course, the rest 5 days going on another course. The total treatment courses lasted 1 month, too.


RESULTS
The visual acuity in group A was remarkably improved while that in group B did not change. The extravasated retinal blood was evidently absorbed in 92.7% of the cases in group A and in 66.7% of those in group B. The difference was significant. Fundus III also improved the retinal circulation, decreased the whole blood viscosity and fibrinogen and reduced leakage of the retinal capillaries. The total effective rates were 83.7% in group A and 53.7% in group B with significant statistical difference between the 2 groups (P < 0.01).


CONCLUSIONS
Fundus III may alleviate retinal edema and necroses, improve the recovering of visual acuity, the retinal microcirculation, the rate of absorbing of retinal haemorrhage and treat RVO, and the curative effect is better than urokinase.
Deng
Y
Y
Department of Ophthalmology, Teaching Hospital of Chengdu College of TCM, China.
Wang
M
M
Duan
J
J
D000328:Adult; D000368:Aged; D002932:Cineangiography; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005451:Fluorescein Angiography; D006801:Humans; D008297:Male; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000188:drug therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D014792:Visual Acuity
D004365:Drugs, Chinese Herbal; D005343:Fibrinolytic Agents; D014568:Urokinase-Type Plasminogen Activator